These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 25517713)
1. Glucocorticoids and mepolizumab in eosinophilic asthma. Iikura M; Hojo M; Sugiyama H N Engl J Med; 2014 Dec; 371(25):2433-4. PubMed ID: 25517713 [No Abstract] [Full Text] [Related]
2. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med; 2015 Apr; 372(18):1777. PubMed ID: 25860645 [No Abstract] [Full Text] [Related]
3. Anti-IL5 therapy for asthma and beyond. Mukherjee M; Sehmi R; Nair P World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744 [TBL] [Abstract][Full Text] [Related]
4. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Hilvering B; Xue L; Pavord ID Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924 [TBL] [Abstract][Full Text] [Related]
11. Biologic therapies targeting eosinophils: current status and future prospects. Legrand F; Klion AD J Allergy Clin Immunol Pract; 2015; 3(2):167-74. PubMed ID: 25754717 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140 [TBL] [Abstract][Full Text] [Related]
13. Inhaled glucocorticoids and COPD exacerbations. Brightling CE; Pavord ID; Bafadhel M N Engl J Med; 2015 Jan; 372(1):93. PubMed ID: 25551538 [No Abstract] [Full Text] [Related]
14. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Hendeles L; Khan YR; Shuster JJ; Chesrown SE; Abu-Hasan M Ann Allergy Asthma Immunol; 2015 Jan; 114(1):58-62.e2. PubMed ID: 25528738 [TBL] [Abstract][Full Text] [Related]
15. Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study. Brzostek D; Kokot M Postepy Dermatol Alergol; 2014 Dec; 31(6):372-9. PubMed ID: 25610352 [TBL] [Abstract][Full Text] [Related]
16. Type 2 inflammation in asthma--present in most, absent in many. Fahy JV Nat Rev Immunol; 2015 Jan; 15(1):57-65. PubMed ID: 25534623 [TBL] [Abstract][Full Text] [Related]
17. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments. Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898 [TBL] [Abstract][Full Text] [Related]
18. Tiotropium as an add-on therapy in patients with symptomatic asthma. Chung KF Lancet Respir Med; 2015 May; 3(5):331-3. PubMed ID: 25682231 [No Abstract] [Full Text] [Related]
19. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Lai T; Wang S; Xu Z; Zhang C; Zhao Y; Hu Y; Cao C; Ying S; Chen Z; Li W; Wu B; Shen H Sci Rep; 2015 Feb; 5():8191. PubMed ID: 25645133 [TBL] [Abstract][Full Text] [Related]